Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.